We standardize the journey from first expression to clinical supply with a risk-based, QbD approach. That means structured host selection and clone assessment (productivity, stability, product quality), media/feed optimization, and a bioreactor strategy tailored to the modality (batch, fed-batch, or perfusion). In parallel, we design the downstream train—capture, intermediate, polishing, and UF/DF—so yield, purity, and cycle time are optimized together with phase-appropriate analytical packages aligned to ICH expectations.
Our scale-down models mirror GMP unit operations, enabling data-driven Design of Experiments (DoE), clear CPP↔CQA mapping, and the definition of an evidence-based control strategy with IPCs/PAT where appropriate. The result is a process that transfers cleanly into manufacturing—reducing variability, de-risking engineering runs and tech transfer, and ultimately accelerating batch release and regulatory progress.
